News & Updates

Show Multimedia Only
Final PROpel data confirm OS advantage with abiraterone plus olaparib
Final PROpel data confirm OS advantage with abiraterone plus olaparib
01 Mar 2023 byJairia Dela Cruz

The combination of olaparib plus abiraterone in the first-line treatment of metastatic castration-resistant prostate cancer (mCRPC) appears to show a consistent trend toward overall survival (OS) benefit, according to the results of the final prespecified analysis of the phase III PROpel study presented at ASCO GU 2023.

Final PROpel data confirm OS advantage with abiraterone plus olaparib
01 Mar 2023